Findings

What do systematic reviews say?

2,640 questions · 2,709 findings · 446 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 593 · 21.9%GRADE not reported 241 · 8.9%Very low 538 · 19.9%Low 706 · 26.1%Moderate 516 · 19%High 115 · 4.2%

Prone vs supine

Long‐term complications (neurodevelopmental) · neonates with mechanical ventilation

The review found no eligible studies for this question.

1 finding from 1 review

Infant position in neonates receiving mechanical ventilation 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Lateral vs supine

Long‐term complications (neurodevelopmental) · neonates with mechanical ventilation

The review found no eligible studies for this question.

1 finding from 1 review

Infant position in neonates receiving mechanical ventilation 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Lateral vs supine

Long‐term complications (bronchopulmonary dysplasia, chronic lung disease) · neonates with mechanical ventilation

The review found no eligible studies for this question.

1 finding from 1 review

Infant position in neonates receiving mechanical ventilation 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Prone vs supine

Long‐term complications (bronchopulmonary dysplasia, chronic lung disease) · neonates with mechanical ventilation

The review found no eligible studies for this question.

1 finding from 1 review

Infant position in neonates receiving mechanical ventilation 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Corticosteroids vs placebo

Prolongation of time to loss of ambulation ‐ not reported · patients with Duchenne muscular dystrophy

The review found no eligible studies for this question.

1 finding from 1 review

Corticosteroids for the treatment of Duchenne muscular dystrophy 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Deflazacort vs prednisone

Prolongation of time to loss of ambulation ‐ not reported · patients with Duchenne muscular dystrophy

The review found no eligible studies for this question.

1 finding from 1 review

Corticosteroids for the treatment of Duchenne muscular dystrophy 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Weekend‐only vs prednisone

Prolongation of time to loss of ambulation ‐ not reported · patients with Duchenne muscular dystrophy

The review found no eligible studies for this question.

1 finding from 1 review

Corticosteroids for the treatment of Duchenne muscular dystrophy 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Multi‐modal hand therapy vs normal activities and advice

Improvement in functional ability · people who have had carpal tunnel release surgery

1 finding from 1 review

Rehabilitation following carpal tunnel release 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 150 participants
Low

RISPERIDONE DEPOT vs placebo

Global state: Relapse ‐ long term ‐ not measured · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS

Adverse events: Specific ‐ prolactin‐related ‐ long term It is unclear how adverse events were reported · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ prolactin‐related ‐ long term It is… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 10.27 [0.59, 180.05]
1 study · 85 participants
Very low

RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS

Weight gain · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ weight increase ‐ long term It is unclear… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.33 [0.56, 3.17]
1 study · 85 participants
Very low

RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS

Adverse events: Nervous system disorders (inc. EPS) ‐ long term It is unclear how adverse events were reported · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Nervous system disorders (inc. EPS) ‐ long term It… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.34 [1.13, 1.58]
1 study · 369 participants
Very low

RISPERIDONE DEPOT vs RISPERIDONE

Relapse · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

RISPERIDONE DEPOT vs placebo

Mental state: clinically significant improvement in mental state ‐ long term1 ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RISPERIDONE DEPOT vs QUETIAPINE

Relapse · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

RISPERIDONE DEPOT vs QUETIAPINE

Mental state ‐ improvement · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

RISPERIDONE DEPOT vs QUETIAPINE

Leaving the study early · patients with schizophrenia

RISPERIDONE DEPOT probably leads to lower leaving the study early: Any reason ‐ long term compared with ORAL QUETIAPINE (moderate certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.84 [0.74, 0.95]
1 study · 666 participants
Moderate

RISPERIDONE DEPOT vs QUETIAPINE

Adverse events: Specific: Mean (SD) weight increase in kg ‐ long term · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 666 participants
Low

RISPERIDONE DEPOT vs ARIPIPRAZOLE

Relapse · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in global state: Relapse (any reason) ‐ long term Assessed by 5 blinded… compared with ORAL ARIPIPRAZOLE (low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.05 [0.83, 1.33]
1 study · 349 participants
Low

RISPERIDONE DEPOT vs ARIPIPRAZOLE

Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · patients with schizophrenia

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 349 participants
Low